Provide feedbackProvide feedback

« Back

J&J returns Priligy product rights to Furiex

Tuesday, May 15 2012 | Comments
Evidence Grade 0 What's This?
Furiex Pharmaceuticals Inc. signed an agreement with Alza Corp. and Janssen Pharmaceutica NV, which are both Johnson & Johnson companies, that sets forth the terms under which Alza and Janssen will transfer the worldwide rights for Priligy (dapoxetine) to Furiex.

Janssen has been marketing Priligy, which is a short-acting, selective serotonin reuptake inhibitor, as an on-demand treatment for premature ejaculation in 15 countries in Europe, Asia and Latin America. Altogether, the drug is approved for that indication in 43 countries, although it is not approved in the United States.

Janssen will continue to manufacture and manage certain clinical and regulatory activities in connection with the product for a predefined period after the closing date of the agreement and will continue to make Priligy available to patients until the marketing authorization rights are transferred, at which time worldwide commercialization of the product will transition to Furiex or its licensee.

The transaction is expected to close in the third quarter.

Alza licensed dapoxetine from Pharmaceutical Product Development Inc. (PPD) in 2000. Furiex was spun off from PPD in 2010.

Print  |  E-mail

Comments

Be the first to write a comment for this article!

You must be logged in to post a comment.